In-vitro evaluation of procoagulant activities of microparticles expressing phosphatidylserine derived from breast cancer cell line MDA-MB-231 treated with Adriamycin

Document Type : Original Article

Authors
Reza Ranjbaran 1
Akbar Hashemi Tayer 2
Maryam Kamravan 2
Mahsa Gorgin 2
1 Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2 Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
10.22034/pjms.2022.701644
Abstract
Introduction: Thromboembolic conditions in cancer patients undergoing chemotherapy are 4 to 7 times higher than
in control patients. The aim of this study is to evaluate the procoagulant activity of microparticles (MPs) expressing phosphatidylserine (PS) derived from breast cancer cell line MDA-MB-231 treated with Adriamycin.
Methods & Materials: In this experimental study, MDA-MB-231 breast cancer cells were treated with concentrations of 0.5, 1, and 2 μM adriamycin for 24 and 48 hours. Using centrifugation technique, the MPs in the cell culture medium were separated from other contents and flow cytometry was used to count and determine the MPs phenotype. At the end, the statistical analysis of the data was done SPSS software version 23 (IBM,USA).
Results: The total number of MPs increased by 11.3 and 11.8 times in 24 and 48 hours treated and 2 μM dose respectively (p<0.001). Almost 49% of all MPs were positive in terms of Annexin V marker, which is an indicator of procoagulant MPs. In the culture medium treated with a dose of 2 μM, the procoagulant activity of MPs at 24 and 48 hours was 42 ± 5.9 nM and 58 ± 6.8 nM PS, respectively, which was more than 14 compared to the control groups. They had an increase (p<0.001).
Conclusion: Adriamycin increases the procoagulant activity of tumor-derived MPs, which can be one of the important and effective reasons for causing thromboembolic conditions in patients undergoing chemotherapy.
 
Keywords
Breast cancer
Microparticles
Adriamycin
1.Acharya UR, Ng EYK, Tan JH, Sree SV.Thermography based breast cancer detection usingtexturefeaturesandsupportvector machine. J MedSyst. 2012;36(3):1503-10.2.Haghbeen M, Tayer AH, Kamravan M, Jahromi AS.Derived Procoagulant Microparticles as Blood-BasedBiomarker of Breast Cancer. Asian Pac J Cancer Prev.021;22(5):1573.3.Timp JF, Braekkan SK, Versteeg HH, CannegieterSC. Epidemiology of cancer-associated venousthrombosis. Blood. 2013;122(10):1712-23.4.Hisada Y, Geddings J, Ay C, Mackman N. Venousthrombosis and cancer: from mouse models to clinicaltrials. J Thromb Haemost. 2015;13(8):1372-82.5. Levitan N, Dowlati A, Remick SC, Tahsildar HI,Sivinski LD, Beyth R, et al. Rates of initial andrecurrent thromboembolic disease among patientswith malignancy versus those without malignancy.Risk analysis using Medicare claims data. Medicine(Baltimore). 1999;78(5):285-91.6.Hisada Y, Mackman N. Cancer-associated pathwaysand biomarkers of venous thrombosis. Blood.2017;130(13):1499-506.7.Walker AJ, West J, Card TR, Crooks C, Kirwan CC,Grainge MJ. When are breast cancer patients athighest risk of venous thromboembolism? Acohortstudy using English health care data. Blood.2016;127(7):849-57.8.Vader P, Breakefield XO, Wood MJ. Extracellularvesicles: emerging targets for cancer therapy. TrendsMol Med. 2014;20(7):385-93.9.Muralidharan-Chari V, Clancy JW, Sedgwick A,D'Souza-Schorey C. Microvesicles: mediators ofextracellular communication during cancer
progression. J Cell Sci. 2010;123(10):1603-11.10.Berghuis AS, Koffijberg H, Prakash J, TerstappenLW, IJzerman MJ.Detecting blood-based biomarkersin metastatic breast cancer: a systematic review oftheir current status and clinical utility. Int J Mol Sci.2017;18(2):363.11.Welsh J, Smith J, Yates K, Greeman J, MaraveyasA, Madden L. Tissue factor expression determines
tumourcellcoagulationkinetics.IntJLabHematol012;34(4):396-402.12.ChangW,FaH,XiaoD,WangJ.Targetingphosphatidylserine for Cancer therapy: prospects andchallenges. Theranostics. 2020;10(20):9214.13.Tayer AH, Amirizadeh N, Ahmadinejad M,Nikougoftar M, Deyhim MR, Zolfaghari S.Procoagulant activity of red blood cell-derivedmicrovesicles during red cell storage. Transfus MedHemother. 2019;46(4):224-30.14.Zhang C, Yang Z, Zhou P, Yu M, Li B, Liu Y, et al.Phosphatidylserine-exposing tmor-derivedmicroparticles exacerbate coagulation and cancercelltransendothelial migration in triple-negative breastcancer. Theranostics. 2021;11(13):644515.Aharon A, Sabbah AR, Issman L, Berkovich H,Copty R, Talmon Y, et al. Effects of low-and highdose chemotherapy agents on thrombogenicproperties of extracellular vesicles derived from breastcancer cell lines. J Thromb Haemost2018;118(03):480-916.Trappenburg MC, van Schilfgaarde M, Bredewold
EO, van Aalderen MC, Spronk HM, Ten Cate H, et al.Elevated numbers and altered subsets of procoagulantmicroparticles in breast cancer patients usingendocrine therapy. Thromb Res. 2011;127(4):363-917.Aharon A, Sabbah A, Ben-Shaul S, Berkovich HLoven D, Brenner B, et al. Chemotherapyadministration to breast cancer patients affectsextracellular vesicles thrombogenicity and function.Oncotarget. 2017;8(38):63265.18. Lima LG, Monteiro RQ. Activation of bloodcoagulation in cancer: implications for tumourprogression. Biosci Rep. 2013;33(5):e0006419. Rautou PE, Mackman N. Microvesicles as riskmarkers for venous thrombosis. Expert Rev Hematol.2013;6(1):91-10120.Geddings JE, Hisada Y, Boulaftali Y, Getz TM,
Whelihan M, Fuentes R, et al. Tissue factor–positivetumor microvesicles activate platelets and enhancethrombosis in mice. J Thromb Haemost.2016;14(1):153-6621.Hron G, Kollars M, Weber H, Sagaster V,Quehenberger P, Eichinger S, et al. Tissue factor-positive microparticles: cellular origin and associationwith coagulation activation in patients with colorectal
cancer. J Thromb Haemost. 2007;97(1):119-23.22.Zwicker JI, Liebman HA, Neuberg D, Lacroix R,Bauer KA, Furie BC, et al. Tumor-derived tissuefactorbearing microparticles are associated withvenous thromboembolic events inmalignancyClinCancerRes2009;15(22):6830-40.23.Bourcy M, Suarez-Carmona M, Lambert J, FrancartM-E, Schroeder H, Delierneux C, et al. Tissue FactorInduced by Epithelial–Mesenchymal TransitionTriggers a Procoagulant State That Drives etastasisof Circulating Tumor CellsEMT-Induced TF Procoagulant Properies ofCTCsCancerRes.2016;76(14):4270-82.24.Yu Y, Böing AN, Hau CM, Hajji N, Ruf W, Sturk A,et al. Tissue factor coagulant activity is regulated bythe plasma membrane microenvironment. J ThrombHaemost. 2018;118(06):990-1000.25. Van der Pol E, Van Gemert MJ, Sturk A, NieuwlandR, Van Leeuwen TG. Single vs. swarm detection ofmicroparticles and exosomes by flow cytometryJThromb Haemost. 2012;10(5):919-30.